Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Jim Van Meerten

Don’t Chase Medpace Stock Here Despite Its Strong Technical Momentum

  • Medpace (MEDP) demonstrates strong technical momentum, maintaining a 100% “Buy” technical opinion from Barchart.
  • Shares are up more than 20% over the past year.
  • Valuation remains a concern, with a trailing P/E of 36.35x.
  • I maintain a “Hold” stance, recommending existing holders use a stop loss due to high volatility and divergent analyst targets.

Today’s Featured Stock

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.